• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.

作者信息

Popat Sanjay, Vieira de Araújo Alexandra, Min Toon, Swansbury John, Dainton Melissa, Wotherspoon Andrew, Lim Eric, Nicholson Andrew G, O'Brien Mary E R

机构信息

Royal Marsden Hospital, London and Surrey, United Kingdom.

出版信息

J Thorac Oncol. 2011 Nov;6(11):1962-3. doi: 10.1097/JTO.0b013e31822eec5e.

DOI:10.1097/JTO.0b013e31822eec5e
PMID:22005476
Abstract
摘要

相似文献

1
Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.伴有外显子19表皮生长因子受体（EGFR）突变和间变性淋巴瘤激酶（ALK）重排的肺腺癌对厄洛替尼有反应。
J Thorac Oncol. 2011 Nov;6(11):1962-3. doi: 10.1097/JTO.0b013e31822eec5e.
2
An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.表皮生长因子受体（EGFR）第19外显子的一种罕见插入突变在酪氨酸激酶抑制剂（TKI）治疗后显示疾病稳定。
J Thorac Oncol. 2013 Dec;8(12):e107-8. doi: 10.1097/JTO.0b013e3182a471e0.
3
First case of A859T epidermal growth factor receptor mutation responding to erlotinib.首例对厄洛替尼有反应的A859T表皮生长因子受体突变病例。
J Thorac Oncol. 2011 Mar;6(3):639-40. doi: 10.1097/JTO.0b013e3182037c0c.
4
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.比较表皮生长因子受体外显子 19 或 21 突变的非小细胞肺癌患者使用吉非替尼和厄洛替尼治疗的临床结局。
J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095.
5
Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.吉非替尼治疗失败且获得性T790M突变后对厄洛替尼反应良好的肺腺癌
J Thorac Oncol. 2008 Apr;3(4):451-2. doi: 10.1097/JTO.0b013e318169e32a.
6
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.表皮生长因子受体酪氨酸激酶抑制剂在携带罕见表皮生长因子受体突变的非小细胞肺癌患者中的活性。
J Thorac Oncol. 2011 Nov;6(11):1895-901. doi: 10.1097/JTO.0b013e318227e8c6.
7
Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.对表皮生长因子受体第19外显子缺失和K-ras G13D突变并存的肺腺癌患者，厄洛替尼治疗反应良好。
J Clin Oncol. 2010 Mar 1;28(7):e111-2. doi: 10.1200/JCO.2009.24.0747. Epub 2009 Dec 14.
8
Two rare exon 21 EGFR mutations in patients treated with gefitinib.两名接受吉非替尼治疗的患者出现罕见的外显子21表皮生长因子受体（EGFR）突变。
J Thorac Oncol. 2013 Apr;8(4):e36-7. doi: 10.1097/JTO.0b013e318286cf9e.
9
Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.两代患有晚期肺腺癌且对厄洛替尼有持久反应的从不吸烟者。
J Thorac Oncol. 2012 Jul;7(7):1200-1. doi: 10.1097/JTO.0b013e318250ed89.
10
Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.厄洛替尼治疗同时存在KIF5B-RET融合基因和EGFR突变的肺腺癌的经验：1例罕见病例报告
J Thorac Oncol. 2014 May;9(5):e37-9. doi: 10.1097/JTO.0000000000000097.

引用本文的文献

1
Comparing Genomic Profiles of Fusion-Positive and Fusion-Negative Nonsmall Cell Lung Cancer Patients.融合阳性与融合阴性非小细胞肺癌患者的基因组图谱比较
Glob Med Genet. 2024 Jun 13;11(2):175-186. doi: 10.1055/s-0044-1787301. eCollection 2024 Jun.
2
Case report: Concomitant mutation and rearrangement in non-small cell lung cancer.病例报告：非小细胞肺癌中的伴随突变和重排
Front Pharmacol. 2023 Aug 29;14:1167959. doi: 10.3389/fphar.2023.1167959. eCollection 2023.
3
Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling.
通过基于DNA的分析揭示多种癌症中潜在可靶向的受体酪氨酸激酶融合图谱。
NPJ Precis Oncol. 2022 Nov 11;6(1):84. doi: 10.1038/s41698-022-00325-0.
4
Analysis of real-word mutations of lung cancer driver genes in five regions of China.中国五个地区肺癌驱动基因的真实世界突变分析。
Transl Cancer Res. 2019 Nov;8(7):2581-2592. doi: 10.21037/tcr.2019.10.28.
5
Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.脑转移肺腺癌患者同时存在 EGFR 突变和 DCTN1-ALK 融合，阿来替尼和奥希替尼的疗效。
Thorac Cancer. 2022 Feb;13(4):637-642. doi: 10.1111/1759-7714.14291. Epub 2021 Dec 28.
6
Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.同时存在表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）突变的患者的遗传和治疗特征。
BMC Cancer. 2021 Oct 15;21(1):1107. doi: 10.1186/s12885-021-08824-2.
7
Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma-a case report and a literature review.IV期肺腺癌中表皮生长因子受体（EGFR）突变与间变性淋巴瘤激酶（ALK）重排并存——1例病例报告及文献综述
Porto Biomed J. 2021 Feb 11;6(1):e124. doi: 10.1097/j.pbj.0000000000000124. eCollection 2021 Jan-Feb.
8
Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors.肿瘤中驱动癌基因的伴随致病突变与融合
Front Oncol. 2021 Jan 15;10:544579. doi: 10.3389/fonc.2020.544579. eCollection 2020.
9
Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report.多灶性肺腺癌中同时存在 EGFR 突变和 ALK 重排：一例报告。
Diagn Pathol. 2020 May 6;15(1):42. doi: 10.1186/s13000-020-00969-1.
10
Incidence of -Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients.印度重排非小细胞肺癌的发病率及克唑替尼在肺腺癌患者中的疗效
Lung Cancer (Auckl). 2020 Feb 24;11:19-25. doi: 10.2147/LCTT.S244366. eCollection 2020.